الفهرس 
Hepatitis B Virus (HBV)Only 14 pages are availabe for public view
 |  | from | 129 |  |  |
| | | from | 129 | | |
Abstract
Hepatitis B virus infection remains a major health problem worldwide with estimates of nearly 400 million chronic HBV surface antigen (HBsAg) carriers. HBV infection may be associated with a large spectrum of clinical manifestations, ranging from very mild and asymptomatic clinical forms to the most severe liver diseases including fulminant hepatitis, cirrhosis, and hepatocellular carcinoma (HCC).
Chronic HDV infections are associated with liver damage that progresses more rapidly than that seen in patients with HBV alone. Approximately 60–79% of patients with chronic hepatitis D develop liver cirrhosis, which is nearly three times higher than type B and C hepatitis, and a large number of these patients die of hepatic failure.
Infection with HDV can occur simultaneously with acute HBV infection or may be superimposed on chronic HBV infection, It is known that coexistent infection with HDV tends to accelerate the progress of chronic HBV infection to chronic hepatitis, cirrhosis and hepatocellular carcinoma.
This study aimed to estimate the the prevalence of HDV among Hepatitis B cases attending or admitted to Kafr El-sheikh Liver Diseases Research Institute and blood transfusion centre, All cases of our study (200 patients) were subjected to full history; clinical examination and seromarkers for HBV and HDV.
The present study found:
revalence of HDV infection among Kafr El-sheikh Liver Diseases Research Institute and blood transfusion centre blood donors in Kafr El-sheikh governorate was 12% .
There was male predominc (83.3%) in anti HDV positive patients (24patients), the majority of them from urban areas (62.5%) and all of them were positive for HBV PCR (DNA).
•There was a highly statistically significant difference between positive and negative HDVAb cases as regard age (P=0.022) while no significant difference as regard sex (P=0.198) and residence (P=0.293).
•There was a highly statistically significant difference between Anti HDVAb positive and negative patients as regard platelet count (P<0.001), serum ALT level (P=0.026), serum AST level (P=0.044) and prothrombin concentration (P<0.001).
•There was a highly statistically significant difference between Anti-HDVAb positive and negative cases regarding HBsAg positivity (P<0.001), HBeAg positivity (p=0.005) and HBV (DNA) PCR (P<0.001).
• There was significant positive correlation between Anti HDVAb Positivity and age (R=0.323, p=0.039), serum level of AST (R=0.332, P=0.05), ALT (R=0.379, p=0.03) and HDV (DNA) PCR (R=0.999,P <0.001) and significant negative correlation as regard platelet count (R= -0.447, P= 0.011) and prothrombin concentration (R= -0.398, P =0.027).